NFE2L2 and cancer: Similarly, Univariate survival analysis revealed that Nrf2-activating MU (HR: 1.68, 95% CI 1.46–1.93) and Nrf2-inactivating MU (HR: 1.79, 95% CI 1.26–2.55) had a significant association with shorter OS for pan-cancer types (Fig. 3C).